Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw unusually-strong trading volume on Friday . Approximately 9,615 shares traded hands during trading, an increase of 38% from the previous session’s volume of 6,973 shares.The stock last traded at $18.54 and had previously closed at $20.40.

Wall Street Analysts Forecast Growth

AAPG has been the topic of a number of recent research reports. BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Two research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The company has a 50 day simple moving average of $18.76 and a 200 day simple moving average of $22.67.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International in the 3rd quarter valued at approximately $383,000. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the second quarter worth $391,000. Finally, UBS Group AG grew its stake in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.